Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 208

1.

Original Antigenic Sin and Respiratory Syncytial Virus Vaccines.

Tripp RA, Power UF.

Vaccines (Basel). 2019 Sep 6;7(3). pii: E107. doi: 10.3390/vaccines7030107.

2.

A Potent Neutralizing Site III-Specific Human Antibody Neutralizes Human Metapneumovirus In Vivo.

Bar-Peled Y, Diaz D, Pena-Briseno A, Murray J, Huang J, Tripp RA, Mousa JJ.

J Virol. 2019 Sep 12;93(19). pii: e00342-19. doi: 10.1128/JVI.00342-19. Print 2019 Oct 1.

PMID:
31292250
3.

MicroRNA and Nonsense Transcripts as Putative Viral Evasion Mechanisms.

Bakre AA, Maleki A, Tripp RA.

Front Cell Infect Microbiol. 2019 May 8;9:152. doi: 10.3389/fcimb.2019.00152. eCollection 2019.

4.

Role of Type I Interferon (IFN) in the Respiratory Syncytial Virus (RSV) Immune Response and Disease Severity.

Hijano DR, Vu LD, Kauvar LM, Tripp RA, Polack FP, Cormier SA.

Front Immunol. 2019 Mar 26;10:566. doi: 10.3389/fimmu.2019.00566. eCollection 2019. Review.

5.

Human Norovirus: Experimental Models of Infection.

Todd KV, Tripp RA.

Viruses. 2019 Feb 12;11(2). pii: E151. doi: 10.3390/v11020151. Review.

6.

Generation of H7N9-specific human polyclonal antibodies from a transchromosomic goat (caprine) system.

Wu H, Fan Z, Brandsrud M, Meng Q, Bobbitt M, Regouski M, Stott R, Sweat A, Crabtree J, Hogan RJ, Tripp RA, Wang Z, Polejaeva IA, Sullivan EJ.

Sci Rep. 2019 Jan 23;9(1):366. doi: 10.1038/s41598-018-36961-5.

7.

Verdinexor (KPT-335), a Selective Inhibitor of Nuclear Export, Reduces Respiratory Syncytial Virus Replication In Vitro.

Jorquera PA, Mathew C, Pickens J, Williams C, Luczo JM, Tamir S, Ghildyal R, Tripp RA.

J Virol. 2019 Feb 5;93(4). pii: e01684-18. doi: 10.1128/JVI.01684-18. Print 2019 Feb 15.

8.

Susceptibility of influenza viruses to hypothiocyanite and hypoiodite produced by lactoperoxidase in a cell-free system.

Patel U, Gingerich A, Widman L, Sarr D, Tripp RA, Rada B.

PLoS One. 2018 Jul 25;13(7):e0199167. doi: 10.1371/journal.pone.0199167. eCollection 2018.

9.

An innate defense peptide BPIFA1/SPLUNC1 restricts influenza A virus infection.

Akram KM, Moyo NA, Leeming GH, Bingle L, Jasim S, Hussain S, Schorlemmer A, Kipar A, Digard P, Tripp RA, Shohet RV, Bingle CD, Stewart JP.

Mucosal Immunol. 2018 May;11(3):1008. doi: 10.1038/mi.2017.109.

PMID:
29845976
10.

Anti-respiratory syncytial virus (RSV) G monoclonal antibodies reduce lung inflammation and viral lung titers when delivered therapeutically in a BALB/c mouse model.

Caidi H, Miao C, Thornburg NJ, Tripp RA, Anderson LJ, Haynes LM.

Antiviral Res. 2018 Jun;154:149-157. doi: 10.1016/j.antiviral.2018.04.014. Epub 2018 Apr 17.

PMID:
29678551
11.

Enhancing viral vaccine production using engineered knockout vero cell lines - A second look.

Hoeksema F, Karpilow J, Luitjens A, Lagerwerf F, Havenga M, Groothuizen M, Gillissen G, Lemckert AAC, Jiang B, Tripp RA, Yallop C.

Vaccine. 2018 Apr 12;36(16):2093-2103. doi: 10.1016/j.vaccine.2018.03.010. Epub 2018 Mar 16.

12.

Native Human Monoclonal Antibodies with Potent Cross-Lineage Neutralization of Influenza B Viruses.

Vigil A, Estélles A, Kauvar LM, Johnson SK, Tripp RA, Wittekind M.

Antimicrob Agents Chemother. 2018 Apr 26;62(5). pii: e02269-17. doi: 10.1128/AAC.02269-17. Print 2018 May.

13.

Verdinexor Targeting of CRM1 is a Promising Therapeutic Approach against RSV and Influenza Viruses.

Pickens JA, Tripp RA.

Viruses. 2018 Jan 21;10(1). pii: E48. doi: 10.3390/v10010048. Review.

14.

Corrigendum to "Molecular epidemiology of swine influenza A viruses in the Southeastern United States, highlights regional differences in circulating strains'' [Vet. Microbiol. 211 (2017) 174-179].

Kyriakis CS, Zhang M, Wolf S, Jones LP, Shim BS, Chocallo AH, Hanson JM, Jia M, Liu D, Tripp RA.

Vet Microbiol. 2018 Feb;214:154. doi: 10.1016/j.vetmic.2017.11.034. Epub 2017 Dec 21. No abstract available.

15.

A universal mammalian vaccine cell line substrate.

Murray J, Todd KV, Bakre A, Orr-Burks N, Jones L, Wu W, Tripp RA.

PLoS One. 2017 Nov 27;12(11):e0188333. doi: 10.1371/journal.pone.0188333. eCollection 2017.

16.

Respiratory Syncytial Virus: Targeting the G Protein Provides a New Approach for an Old Problem.

Tripp RA, Power UF, Openshaw PJM, Kauvar LM.

J Virol. 2018 Jan 17;92(3). pii: e01302-17. doi: 10.1128/JVI.01302-17. Print 2018 Feb 1. Review.

17.

Molecular epidemiology of swine influenza A viruses in the Southeastern United States, highlights regional differences in circulating strains.

Kyriakis CS, Zhang M, Wolf S, Jones LP, Shim BS, Chocallo AH, Hanson JM, Jia M, Liu D, Tripp RA.

Vet Microbiol. 2017 Nov;211:174-179. doi: 10.1016/j.vetmic.2017.10.016. Epub 2017 Oct 18. Erratum in: Vet Microbiol. 2017 Dec 20;:.

18.

MicroRNA-134 regulates poliovirus replication by IRES targeting.

Bakre AA, Shim BS, Tripp RA.

Sci Rep. 2017 Oct 4;7(1):12664. doi: 10.1038/s41598-017-12860-z.

19.

Vaccination with Recombinant Parainfluenza Virus 5 Expressing Neuraminidase Protects against Homologous and Heterologous Influenza Virus Challenge.

Mooney AJ, Gabbard JD, Li Z, Dlugolenski DA, Johnson SK, Tripp RA, He B, Tompkins SM.

J Virol. 2017 Nov 14;91(23). pii: e01579-17. doi: 10.1128/JVI.01579-17. Print 2017 Dec 1.

20.

The Central Conserved Region (CCR) of Respiratory Syncytial Virus (RSV) G Protein Modulates Host miRNA Expression and Alters the Cellular Response to Infection.

Bakre AA, Harcourt JL, Haynes LM, Anderson LJ, Tripp RA.

Vaccines (Basel). 2017 Jul 3;5(3). pii: E16. doi: 10.3390/vaccines5030016.

21.

Roles of Non-coding RNAs in Respiratory Syncytial Virus (RSV) Infection.

Tripp RA, Bakre AA.

Curr Top Microbiol Immunol. 2018;419:215-241. doi: 10.1007/82_2017_32. Review.

PMID:
28646339
22.

A Sendai virus recombinant vaccine expressing a gene for truncated human metapneumovirus (hMPV) fusion protein protects cotton rats from hMPV challenge.

Russell CJ, Jones BG, Sealy RE, Surman SL, Mason JN, Hayden RT, Tripp RA, Takimoto T, Hurwitz JL.

Virology. 2017 Sep;509:60-66. doi: 10.1016/j.virol.2017.05.021. Epub 2017 Jun 9.

23.

Respiratory syncytial virus: prospects for new and emerging therapeutics.

Jorquera PA, Tripp RA.

Expert Rev Respir Med. 2017 Aug;11(8):609-615. doi: 10.1080/17476348.2017.1338567. Epub 2017 Jun 14. Review.

PMID:
28574729
24.

An innate defense peptide BPIFA1/SPLUNC1 restricts influenza A virus infection.

Akram KM, Moyo NA, Leeming GH, Bingle L, Jasim S, Hussain S, Schorlemmer A, Kipar A, Digard P, Tripp RA, Shohet RV, Bingle CD, Stewart JP.

Mucosal Immunol. 2018 Jan;11(1):71-81. doi: 10.1038/mi.2017.45. Epub 2017 May 17. Erratum in: Mucosal Immunol. 2018 May;11(3):1008.

25.

Targeting the pro-inflammatory factor CCL2 (MCP-1) with Bindarit for influenza A (H7N9) treatment.

Wolf S, Johnson S, Perwitasari O, Mahalingam S, Tripp RA.

Clin Transl Immunology. 2017 Mar 31;6(3):e135. doi: 10.1038/cti.2017.8. eCollection 2017 Mar.

26.

Enhanced immunogenicity following miR-155 incorporation into the influenza A virus genome.

Izzard L, Dlugolenski D, Xia Y, McMahon M, Middleton D, Tripp RA, Stambas J.

Virus Res. 2017 May 2;235:115-120. doi: 10.1016/j.virusres.2017.04.002. Epub 2017 Apr 7.

27.

Mutating the CX3C Motif in the G Protein Should Make a Live Respiratory Syncytial Virus Vaccine Safer and More Effective.

Boyoglu-Barnum S, Todd SO, Meng J, Barnum TR, Chirkova T, Haynes LM, Jadhao SJ, Tripp RA, Oomens AG, Moore ML, Anderson LJ.

J Virol. 2017 Apr 28;91(10). pii: e02059-16. doi: 10.1128/JVI.02059-16. Print 2017 May 15.

28.

MicroRNA screening identifies miR-134 as a regulator of poliovirus and enterovirus 71 infection.

Orr-Burks NL, Shim BS, Wu W, Bakre AA, Karpilow J, Tripp RA.

Sci Data. 2017 Mar 1;4:170023. doi: 10.1038/sdata.2017.23.

29.

Development of improved vaccine cell lines against rotavirus.

Wu W, Orr-Burks N, Karpilow J, Tripp RA.

Sci Data. 2017 Mar 1;4:170021. doi: 10.1038/sdata.2017.21.

30.
31.

Antiviral Efficacy of Verdinexor In Vivo in Two Animal Models of Influenza A Virus Infection.

Perwitasari O, Johnson S, Yan X, Register E, Crabtree J, Gabbard J, Howerth E, Shacham S, Carlson R, Tamir S, Tripp RA.

PLoS One. 2016 Nov 28;11(11):e0167221. doi: 10.1371/journal.pone.0167221. eCollection 2016.

32.

ADAMTS5 Is a Critical Regulator of Virus-Specific T Cell Immunity.

McMahon M, Ye S, Izzard L, Dlugolenski D, Tripp RA, Bean AG, McCulloch DR, Stambas J.

PLoS Biol. 2016 Nov 17;14(11):e1002580. doi: 10.1371/journal.pbio.1002580. eCollection 2016 Nov.

33.

Virologic Differences Do Not Fully Explain the Diversification of Swine Influenza Viruses in the United States.

Fabrizio TP, Sun Y, Yoon SW, Jeevan T, Dlugolenski D, Tripp RA, Tang L, Webby RJ.

J Virol. 2016 Oct 28;90(22):10074-10082. doi: 10.1128/JVI.01218-16. Print 2016 Nov 15.

34.

Coated protein nanoclusters from influenza H7N9 HA are highly immunogenic and induce robust protective immunity.

Wang L, Chang TZ, He Y, Kim JR, Wang S, Mohan T, Berman Z, Tompkins SM, Tripp RA, Compans RW, Champion JA, Wang BZ.

Nanomedicine. 2017 Jan;13(1):253-262. doi: 10.1016/j.nano.2016.09.001. Epub 2016 Sep 10.

35.

Passive narcosis for anesthesia induction in cotton rats (Sigmodon hispidus).

Hanson JM, Anderson LJ, Williams CM, Jorquera P, Tripp RA.

Lab Anim (NY). 2016 Aug 23;45(9):333-7. doi: 10.1038/laban.1084.

PMID:
27551803
36.

MicroRNA Profiling from RSV-Infected Biofluids, Whole Blood, and Tissue Samples.

Anderson L, Jorquera PA, Tripp RA.

Methods Mol Biol. 2016;1442:195-208. doi: 10.1007/978-1-4939-3687-8_14.

PMID:
27464696
37.

Quantification of RSV Infectious Particles by Plaque Assay and Immunostaining Assay.

Jorquera PA, Tripp RA.

Methods Mol Biol. 2016;1442:33-40. doi: 10.1007/978-1-4939-3687-8_3.

PMID:
27464685
38.

Human Respiratory Syncytial Virus: An Introduction.

Jorquera PA, Anderson L, Tripp RA.

Methods Mol Biol. 2016;1442:1-12. doi: 10.1007/978-1-4939-3687-8_1.

PMID:
27464683
39.

Development of a Zika vaccine.

Tripp RA, Ross TM.

Expert Rev Vaccines. 2016 Sep;15(9):1083-5. doi: 10.1080/14760584.2016.1192474. Epub 2016 Jun 6. Review. No abstract available.

PMID:
27212079
40.

MicroRNA Regulation of Human Genes Essential for Influenza A (H7N9) Replication.

Wolf S, Wu W, Jones C, Perwitasari O, Mahalingam S, Tripp RA.

PLoS One. 2016 May 11;11(5):e0155104. doi: 10.1371/journal.pone.0155104. eCollection 2016.

41.

Production of Potent Fully Human Polyclonal Antibodies against Ebola Zaire Virus in Transchromosomal Cattle.

Dye JM, Wu H, Hooper JW, Khurana S, Kuehne AI, Coyle EM, Ortiz RA, Fuentes S, Herbert AS, Golding H, Bakken RA, Brannan JM, Kwilas SA, Sullivan EJ, Luke TC, Smith G, Glenn G, Li W, Ye L, Yang C, Compans RW, Tripp RA, Jiao JA.

Sci Rep. 2016 Apr 25;6:24897. doi: 10.1038/srep24897.

42.

Visible-Light-Activated Bactericidal Functions of Carbon "Quantum" Dots.

Meziani MJ, Dong X, Zhu L, Jones LP, LeCroy GE, Yang F, Wang S, Wang P, Zhao Y, Yang L, Tripp RA, Sun YP.

ACS Appl Mater Interfaces. 2016 May 4;8(17):10761-6. doi: 10.1021/acsami.6b01765. Epub 2016 Apr 22.

43.

Erratum to: Serial passage in ducks of a low-pathogenic avian influenza virus isolated from a chicken reveals a high mutation rate in the hemagglutinin that is likely due to selection in the host.

Ridenour C, Williams SM, Jones L, Tompkins SM, Tripp RA, Mundt E.

Arch Virol. 2016 May;161(5):1423. doi: 10.1007/s00705-016-2837-4. No abstract available.

PMID:
27038824
44.

MicroRNA-555 has potent antiviral properties against poliovirus.

Shim BS, Wu W, Kyriakis CS, Bakre A, Jorquera PA, Perwitasari O, Tripp RA.

J Gen Virol. 2016 Mar;97(3):659-68. doi: 10.1099/jgv.0.000372. Epub 2015 Dec 18.

PMID:
26683768
45.

Understanding respiratory syncytial virus (RSV) vaccine development and aspects of disease pathogenesis.

Jorquera PA, Anderson L, Tripp RA.

Expert Rev Vaccines. 2016;15(2):173-87. doi: 10.1586/14760584.2016.1115353. Epub 2015 Dec 5. Review.

PMID:
26641318
46.

Hypothiocyanite produced by human and rat respiratory epithelial cells inactivates extracellular H1N2 influenza A virus.

Gingerich A, Pang L, Hanson J, Dlugolenski D, Streich R, Lafontaine ER, Nagy T, Tripp RA, Rada B.

Inflamm Res. 2016 Jan;65(1):71-80. doi: 10.1007/s00011-015-0892-z. Epub 2015 Nov 25.

PMID:
26608498
47.

Engineering Enhanced Vaccine Cell Lines To Eradicate Vaccine-Preventable Diseases: the Polio End Game.

van der Sanden SM, Wu W, Dybdahl-Sissoko N, Weldon WC, Brooks P, O'Donnell J, Jones LP, Brown C, Tompkins SM, Oberste MS, Karpilow J, Tripp RA.

J Virol. 2015 Nov 18;90(4):1694-704. doi: 10.1128/JVI.01464-15. Print 2016 Feb 15.

48.

Layer-By-Layer Nanoparticle Vaccines Carrying the G Protein CX3C Motif Protect against RSV Infection and Disease.

Jorquera PA, Oakley KE, Powell TJ, Palath N, Boyd JG, Tripp RA.

Vaccines (Basel). 2015 Oct 12;3(4):829-49. doi: 10.3390/vaccines3040829.

49.

Detection of neuraminidase stalk motifs associated with enhanced N1 subtype influenza A virulence via Raman spectroscopy.

Choi J, Martin SJ, Tripp RA, Tompkins SM, Dluhy RA.

Analyst. 2015 Nov 21;140(22):7748-60. doi: 10.1039/c5an00977d.

50.

Induction and Antagonism of Antiviral Responses in Respiratory Syncytial Virus-Infected Pediatric Airway Epithelium.

Villenave R, Broadbent L, Douglas I, Lyons JD, Coyle PV, Teng MN, Tripp RA, Heaney LG, Shields MD, Power UF.

J Virol. 2015 Dec;89(24):12309-18. doi: 10.1128/JVI.02119-15. Epub 2015 Sep 30.

Supplemental Content

Loading ...
Support Center